Inventor · disambiguated record
William Zuercher
Also filed as: ZUERCHER WILLIAM · ZUERCHER WILLIAM J · ZUERCHER WILLIAM JOHN
8 granted patents·3 pending applications·10 citations·filing 2004–2025
81Inventor score
Files withDermavant Sciences GmbH5SMITHKLINE BEECHAM CORP4GLAXOSMITHKLINE LLC1VIROKYNE THERAPEUTICS LLC1
Top patents by PatentIndex Score
11 records- 0190US11827605B2Isoquinoline compounds and their use in treating AhR imbalanceDermavant Sciences GmbH·Filed 2022·Granted Nov 28, 2023·1 cites·18 claims
- 0286US11267788B2Isoquinoline compounds and their use in treating AhR imbalanceDermavant Sciences GmbH·Filed 2021·Granted Mar 8, 2022·1 cites·10 claims
- 0383US12252471B2Isoquinoline compounds and their use in treating AhR imbalanceDermavant Sciences GmbH·Filed 2023·Granted Mar 18, 2025·0 cites·7 claims
- 0477US7405303B2Substituted quinoline compounds for use as selective estrogen receptor modulatorSMITHKLINE BEECHAM CORP·Filed 2005·Granted Jul 29, 2008·5 cites·14 claims
- 0575US11548853B2Isoquinoline compounds and their use in treating AhR imbalanceDermavant Sciences GmbH·Filed 2022·Granted Jan 10, 2023·0 cites·23 claims
- 0672US2025282730A1ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCEDermavant Sciences GmbH·Filed 2025·Application pending·0 cites
- 0771US7569601B2Cycloalkylidene compounds as modulators of estrogen receptorSMITHKLINE BEECHAM CORP·Filed 2007·Granted Aug 4, 2009·1 cites·15 claims
- 0864US7799828B2Cycloalkylidene compounds as modulators of estrogen receptorGLAXOSMITHKLINE LLC·Filed 2009·Granted Sep 21, 2010·0 cites·14 claims
- 0963US7560589B2Cycloalkylidene compounds as modulators of estrogen receptorSMITHKLINE BEECHAM CORP·Filed 2004·Granted Jul 14, 2009·2 cites·4 claims
- 1043US2024309004A1Selective cyclin-dependent kinase inhibitors and methods of therapeutic use thereofVIROKYNE THERAPEUTICS LLC·Filed 2022·Application pending·0 cites
- 1142US2008221176A1Chemical CompoundsSMITHKLINE BEECHAM CORP·Filed 2006·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →